Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089841 | 0.97 | TP53 (0.38) | TP53MEN1KMT2AMAPK8P2RX7 | |
| SCHEMBL10089873 | 0.95 | MAPK8 (0.36) | TP53MAPK8P2RX7NTRK1 | |
| SCHEMBL10089883 | 0.95 | P2RX7 (0.36) | TP53MEN1KMT2AP2RX7PPARG | |
| SCHEMBL10089888 | 0.94 | TP53 (0.34) | TP53DHODHMEN1KMT2AP2RX7 | |
| SCHEMBL10090015 | 0.93 | CARM1 (0.37) | DHODHMEN1KMT2AMAPK8 | |
| SCHEMBL10089867 | 0.93 | TP53 (0.33) | TP53MEN1KMT2AP2RX7SCN10A | |
| SCHEMBL10089973 | 0.93 | P2RX7 (0.36) | TP53P2RX7 | |
| SCHEMBL10089967 | 0.93 | DHODH (0.36) | DHODHPPARGNTRK1 | |
| SCHEMBL10089937 | 0.93 | HSD17B13 (0.40) | MAPK8 | |
| SCHEMBL10089870 | 0.92 | KMT2A (0.36) | DHODHKMT2APPARGNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582695-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES WITH CYCLICAL SIDE CHAINS | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | TP53 3397/4885DHODH 237/4885MEN1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.